European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

I was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was – did the company have any designs on entering the viral vector-based gene therapy ...

TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

Novartis plans to build and expand 10 U.S. facilities New facilities include six manufacturing plants and a research and development site The construction will take place over five years, create ...

Besides, Novartis, Johnson & Johnson plans to spend $55 billion over four years on domestic manufacturing, research and technology. Merck announced plans to spend $1 billion on a vaccine ...

Amid renewed threats of import tariffs on pharmaceuticals from the Trump administration, Novartis plans to spend $23 billion over the next five years to expand its manufacturing, research and ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...